| Spike glycoprotein |
S, 2 |
CR3022 Fab Heavy Chain
CR3022 Fab Light Chain |
~ |
7A5S |
Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. |
Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement) |
Electron Microscopy |
3.9 |
33087721 |
3D view |
| Spike glycoprotein |
S, 2 |
CR3022 Fab Heavy Chain
CR3022 Fab Light Chain |
~ |
7A5R |
Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. |
Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement) |
Electron Microscopy |
3.7 |
33087721 |
3D view |
| Spike glycoprotein |
S, 2 |
Antibody Cr3022, Antibody light chain, Nanobody |
~ |
6YZ7 |
Structural characterisation of a nanobody derived from a naive library that neutralises SARS-CoV-2 |
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex |
X-ray diffraction |
3.3 |
To be published |
3D view |
| Spike glycoprotein |
S, 2 |
Nanobody, EY6A heavy chain, EY6A light chain |
~ |
6ZCZ |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody. |
X-ray diffraction |
2.65 |
32737466 |
3D view |
| Spike glycoprotein |
S, 2 |
EY6A heavy chain, EY6A light chain |
~ |
6ZDH |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab |
Electron Microscopy |
3.7 |
32737466 |
3D view |
| Spike glycoprotein |
S, 2 |
EY6A heavy chain, EY6A light chain |
~ |
6ZDG |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab |
Electron Microscopy |
4.7 |
32737466 |
3D view |
| RBD |
S, 2 |
EY6A Fab |
~ |
6ZER |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab |
X-ray diffraction |
3.8 |
32737466 |
3D view |
| Spike glycoprotein |
S, 2 |
EY6A heavy chain, EY6A light chain |
~ |
6ZFO |
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. |
Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab |
Electron Microscopy |
4.4 |
32737466 |
3D view |
| Surface glycoprotein |
S |
STE90-C11 Fab |
~ |
7B3O |
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations |
Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab |
X-ray diffraction |
2 |
|
3D view |
| Spike glycoprotein |
S,2 |
CR3022 heavy chain, CR3022 Light chain, Nanobody H11-H4 |
~ |
6ZH9 |
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. |
Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2) |
X-ray diffraction |
3.31 |
32661423 |
3D view |
| Spike glycoprotein (A,E chains) |
S,2 |
CR3022 Fab |
~ |
6YLA |
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. |
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab |
X-ray diffraction |
2.42 |
32585135 |
3D view |
| Spike glycoprotein |
S,2 |
CR3022 Fab |
~ |
6YM0 |
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. |
Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1) |
X-ray diffraction |
4.36 |
32585135 |
3D view |
| Spike glycoprotein |
S,2 |
IgG H chain, IgG L chain |
~ |
6YOR |
Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. |
Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab |
Electron Microscopy |
3.3, 3.9 |
32585135 |
3D view |
| Spike glycoprotein |
S,2 |
CR3022 antibody, H11-D4 |
~ |
6Z2M |
Structural characterisation of a nanobody derived from a naive library that neutralises SARS-CoV-2 |
H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex |
X-ray diffraction |
2.71 |
To be published |
3D view |
| Spike glycoprotein - S1 |
S,2 |
CV07-250 ( heavy and light chain) |
~ |
6XKQ |
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-250 |
X-ray diffraction |
2.55 |
33058755 |
3D view |
| Spike protein S1 |
S,2 |
CV07-270 (heavy and light chain) |
~ |
6XKP |
A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270 |
X-ray diffraction |
2.72 |
33058755 |
3D view |
| Spike protein |
S,2 |
3C1 mAb ( heavy chain and light chain) |
~ |
7DD2 |
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. |
S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab. |
Electron Microscopy |
5.6 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| SARC-CoV2 S protein |
S,2 |
Heavy and light chain of 3C1 fab |
~ |
7DCC |
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. |
S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with a 3C1 Fab |
Electron Microscopy |
4.3 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| Spike glycoprotein |
S,2 |
The heavy and light chain of 3C1 fab that binds with the up RBD |
~ |
7DCX |
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. |
S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab. |
Electron Microscopy |
5.9 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| Spike glycoprotein |
S,2 |
The heavy and light chain of 3C1 fab |
~ |
7DD8 |
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. |
S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab |
Electron Microscopy |
7.5 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| Spike glycoprotein |
S,2 |
S2M11 Fab fragment (heavy and light chain) |
~ |
7K43 |
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. |
SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment |
Electron Microscopy |
2.6 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| Spike glycoprotein |
S,2 |
S2E12 neutralizing antibody Fab fragment (heavy and light chain) |
|
7K45 |
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. |
SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of the RBD and Fab variable domains) |
Electron Microscopy |
3.7 |
32972994 |
3D view |
| Spike glycoprotein |
S,2 |
Heavy and light chain of 2H2 Fab |
~ |
7DK6 |
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections |
S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab. |
Electron Microscopy |
4.3 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| Spike glycoprotein |
S,2 |
Heavy and light chain of 2H2 Fab |
~ |
7DK7 |
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections |
S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab. |
Electron Microscopy |
9.7 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| Spike glycoprotein |
S,2 |
Heavy and light chain of 2H2 Fab |
~ |
7DK4 |
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections |
S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab. |
Electron Microscopy |
3.8 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| Spike glycoprotein |
S,2 |
Heavy and light chain of 2H2 Fab |
~ |
7DK5 |
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections |
S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab |
Electron Microscopy |
13.5 |
Nature Communications volume 12, Article number: 264 (2021) |
3D view |
| Spike glycoprotein |
S,2 |
CB6 heavy and light chain |
~ |
7C01 |
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. |
Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD |
X-ray diffraction |
2.88 |
32454512 |
3D view |
| Spike glycoprotein |
S,2 |
4A8 ( heavy and light chain ) |
~ |
7C2L |
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. |
S protein of SARS-CoV-2 in complex bound with 4A8 |
Electron Microscopy |
3.1 |
32571838 |
3D view |
| SARS-CoV-2 receptor binding domain |
S,2 |
P2B-2F6 ( heavy and light chain ) |
~ |
7BWJ |
Human neutralizing antibodies elicited by SARS-CoV-2 infection. |
Crystal structure of SARS-CoV-2 antibody with RBD |
X-ray diffraction |
2.85 |
32454513 |
3D view |
| Spike glycoprotein |
S,2 |
B38 antibody (heavy and light chain) |
~ |
7BZ5 |
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. |
Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody |
X-ray diffraction |
1.84 |
32404477 |
3D view |
| SARS-CoV-2 Spike glycoprotein |
S,2 |
Ab23-Fab(Heavy and light chain) |
~ |
7BYR |
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. |
BD23-Fab in complex with the S ectodomain trimer |
Electron Microscopy |
3.84 |
32425270 |
3D view |
| Spike glycoprotein |
S,2 |
H014 (heavy and light chain) |
~ |
7CAH |
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. |
The interface of H014 Fab binds to SARS-CoV-2 S |
Electron Microscopy |
3.9 |
32703908 |
3D view |
| Spike glycoprotein |
S,2 |
H014 (heavy and light chain) |
~ |
7CAK |
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. |
SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab |
Electron Microscopy |
3.58 |
32703908 |
3D view |
| Spike glycoprotein |
S,2 |
H014 (heavy and light chain) |
~ |
7CAI |
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. |
SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab |
Electron Microscopy |
3.49 |
32703908 |
3D view |
| Spike protein S1 |
S,2 |
P2C-1A3 ( heavy and light chain ) |
~ |
7CDJ |
Crystal structure of SARS-CoV-2 antibody P2C-1A3 and RBD |
Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD |
X-ray diffraction |
3.396 |
To be published |
3D view |
| Spike protein S1 |
S,2 |
Antibody P2C-1F11 heavy and light chain |
~ |
7CDI |
Crystal structure of SARS-CoV-2 antibody P2C-1F11 and RBD |
Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD |
X-ray diffraction |
2.96 |
To be published |
3D view |
| Spike glycoprotein |
S,2 |
BD-604 Fab ( Heavy and light chain) |
~ |
7CH4 |
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. |
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab |
X-ray diffraction |
3.15 |
32970990 |
3D view |
| Spike glycoprotein |
S,2 |
BD-629 Fab ( Heavy and light chain) |
~ |
7CH5 |
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. |
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab |
X-ray diffraction |
2.7 |
32970990 |
3D view |
| SARS-CoV-2 Receptor Binding Domain |
S,2 |
BD-604 Fab ( Heavy and light chain)
BD-368-2 Fab (heavy and light chain) |
~ |
7CHF |
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. |
Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab |
X-ray diffraction |
2.674 |
32970990 |
3D view |
| SARS-coV-2 Receptor Binding Domain |
|
BD-236 Fab (heavy and light chain)
BD-368-2 Fab ( heavy and light chain) |
~ |
7CHE |
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. |
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab |
X-ray diffraction |
3.416 |
32970990 |
3D view |
| Spike glycoprotein |
S,2 |
BD-368-2 Fab (heavy and light chain ) |
~ |
7CHH |
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. |
Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs |
Electron Microscopy |
3.49 |
32970990 |
3D view |
| SARS-coV-2 Receptor Binding Domain |
S,2 |
BD-236 Fab ( heavy and light chain ) |
~ |
7CHB |
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. |
Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab |
X-ray diffraction |
2.4 |
32970990 |
3D view |
| BD-629 Fab H |
S,2 |
BD-629 Fab Heavy chain
IGK@ protein
BD-368-2 Fab ( Heavy and light chain ) |
IGK@ |
7CHC |
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. |
Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab |
X-ray diffraction |
2.71 |
32970990 |
3D view |
| Spike glycoprotein |
S,2 |
Antibody heavy and light chain |
~ |
7CJF |
Crystal structure of SARS-CoV-2 RBD in complex with an antibody Fab |
Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab |
X-ray diffraction |
2.108 |
To be published |
3D view |
| Spike glycoprotein |
S,2 |
P17 and FC05 Fabs (heavy and light chains) |
~ |
7CWU |
Structure-based development of human antibody cocktails against SARS-CoV-2. |
SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail |
Electron Microscopy |
3.5 |
33262454 |
3D view |
| Spike glycoprotein |
S,2 |
FC05 and H014 Fabs ( heavy and light chains ) |
~ |
7CWS |
Structure-based development of human antibody cocktails against SARS-CoV-2. |
SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail |
Electron Microscopy |
3.4 |
33262454 |
3D view |
| Spike glycoprotein |
S,2 |
P17 heavy and light chain |
~ |
7CWM |
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. |
Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed state |
Electron Microscopy |
3.6 |
33262452 |
3D view |
| Spike glycoprotein |
S,2 |
P17-H014 Fab ( heavy and light chain ) |
~ |
7CWN |
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. |
P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein |
Electron Microscopy |
3.2 |
33262452 |
3D view |
| Spike glycoprotein |
S,2 |
P17 ( heavy and light chain ) |
~ |
7CWO |
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. |
SARS-CoV-2 spike protein RBD and P17 fab complex |
Electron Microscopy |
3.9 |
33262452 |
3D view |
| Spike protein S1 |
S,2 |
COVA1-16 (heavy and light chain) |
~ |
7JMW |
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. |
Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutralizing antibody COVA1-16 Fab |
X-ray diffraction |
2.89 |
33242394 |
3D view |
| Spike protein S1 |
S,2 |
COVA2-39 (heavy and light chain) |
~ |
7JMP |
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-39 |
X-ray diffraction |
1.712 |
32743580 |
3D view |
| Spike protein S1 |
S,2 |
COVA2-04 (heavy and light chain) |
~ |
7JMO |
An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-04 |
X-ray diffraction |
2.359 |
32743580 |
3D view |
| Spike glycoprotein |
S,2 |
S2E12 neutralizing antibody Fab fragment (heavy and light chain) |
~ |
7K4N |
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. |
SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment |
Electron Microscopy |
3.3 |
32972994 |
3D view |
| Spike glycoprotein |
S,2 |
S2A4 Fab( heavy and light chain) |
~ |
7JVA |
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. |
SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of the receptor-binding domain and Fab variable domains) |
Electron Microscopy |
3.6 |
32991844 |
3D view |
| Spike glycoprotein |
S,2 |
S2H13 Fab (heavy and light chain) |
~ |
7JV6 |
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. |
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation) |
Electron Microscopy |
3 |
32991844 |
3D view |
| Spike glycoprotein |
S,2 |
S2H13 Fab (heavy and light chain) |
~ |
7JV4 |
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. |
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open) |
Electron Microscopy |
3.4 |
32991844 |
3D view |
| Spike glycoprotein |
S,2 |
S2H13 Fab (heavy and light chain) |
~ |
7JV2 |
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. |
SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of the receptor-binding motif and Fab variable domains) |
Electron Microscopy |
3.5 |
32991844 |
3D view |
| Spike glycoprotein |
S,2 |
autonomous human heavy chain variable domain |
~ |
7JWB |
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. |
SARS CoV2 Spike ectodomain with engineered trimerized VH binder |
Electron Microscopy |
6, 3.2 |
33082574 |
3D view |
| Spike glycoprotein |
S,2 |
S304 Fab (light and heavy chain) |
~ |
7JW0 |
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. |
SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment |
Electron Microscopy |
4.3 |
32991844 |
3D view |
| Spike glycoprotein |
S,2 |
S2A4 Fab (heavy and light chain) |
~ |
7JVC |
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. |
SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment |
Electron Microscopy |
3.3 |
32991844 |
3D view |
| Spike glycoprotein |
S,2 |
C110 Fab (Heavy and light chain) |
~ |
7K8V |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. |
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C110 |
Electron Microscopy |
3.8 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
C119 Fab (Heavy and light chain) |
~ |
7K8W |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. |
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C119 |
Electron Microscopy |
3.6 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
C002 Fab (Heavy and light chain) |
~ |
7K8T |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. |
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C002 (State 2) |
Electron Microscopy |
3.4 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
C104 Fab (Heavy and light chain) |
~ |
7K8U |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies |
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C104 |
Electron Microscopy |
3.8 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
C135 Fab (Heavy and light chain) |
~ |
7K8Z |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies |
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C135 |
Electron Microscopy |
3.5 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
C121 Fab (Heavy and light chain) |
~ |
7K8X |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies |
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 1) |
Electron Microscopy |
3.9, 3.9 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
C121 Fab (Heavy and light chain) |
~ |
7K8Y |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies |
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 2) |
Electron Microscopy |
4.4, 4.4 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
C144 Fab (Heavy and light chain) |
~ |
7K90 |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. |
Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144 |
Electron Microscopy |
3.24 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
C102 Fab (Heavy and light chain) |
~ |
7K8M |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. |
Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C102 |
X-ray diffraction |
3.2 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
Light and heavy chain of Fab domain of monoclonal antibodies S309, S2H14, S304
|
~ |
7JX3 |
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. |
Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology |
X-ray diffraction |
2.65 |
32991844 |
3D view |
| Spike glycoprotein |
S,2 |
C002 Fab (Heavy and light chain) |
~ |
7K8S |
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. |
Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1) |
Electron Microscopy |
3.4 |
33045718 |
3D view |
| Spike glycoprotein |
S,2 |
Antibodies 52, 298 Fab (light and heavy chains) |
~ |
7K9Z |
Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52 |
X-ray diffraction |
2.95 |
To be published |
3D view |
| Surface glycoprotein |
S,2 |
human antibody C1A-C2 Fab (heavy and light chain) |
~ |
7KFX |
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. |
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab) |
X-ray diffraction |
2.226 |
33200128 |
3D view |
| Surface glycoprotein |
S,2 |
Human antibody C1A-F10 Fab (heavy and light chain) |
~ |
7KFY |
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. |
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab) |
X-ray diffraction |
2.157 |
33200128 |
3D view |
| Surface glycoprotein |
S,2 |
Human antibody C1A-B12 Fab (heavy and light chain) |
~ |
7KFV |
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. |
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab) |
X-ray diffraction |
2.102 |
33200128 |
3D view |
| Surface glycoprotein |
S,2 |
Human antibody C1A-B3Fab (heavy and light chain) |
~ |
7KFW |
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. |
Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab) |
X-ray diffraction |
2.792 |
33200128 |
3D view |
| Spike glycoprotein S1 |
S,2 |
CR3022 Fab ( heavy and light chain) |
~ |
6W41 |
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. |
Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022 |
X-ray diffraction |
3.084 |
32245784 |
3D view |
| Spike glycoprotein |
S,2 |
Antibody S309 ( heavy and light chain) |
~ |
6WPT |
Structural and functional analysis of a potent sarbecovirus neutralizing antibody. |
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment (open state) |
Electron Microscopy |
3.7, 3.7 |
32511354 |
3D view |
| Spike glycoprotein |
S,2 |
Antibody S309 ( heavy and light chain) |
~ |
6WPS |
Structural and functional analysis of a potent sarbecovirus neutralizing antibody. |
Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment |
Electron Microscopy |
3.1, 3.1 |
32511354 |
3D view |